Barclays
LYRA

Barclays’s LYRA THERAPEUTICS INC LYRA Stock Holding History

Barclays’s Portfolio LYRA Stock Details LYRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-48
Closed -$430 – 5628
2025
Q2 		$430 Sell
48
-953
-95% -$7.91K ﹤0.01% 5080
2025
Q1 		$6.32K Sell
1,001
-504
-33% -$4.71K ﹤0.01% 4914
2024
Q4 		$15.5K Buy
1,505
+239
+19% +$2.63K ﹤0.01% 4949
2024
Q3 		$16.3K Buy
1,266
+934
+281% +$13.7K ﹤0.01% 4919
2024
Q2 		$4.59K Sell
332
-324
-49% -$36.6K ﹤0.01% 4584
2024
Q1 		$204K Hold
656
– – ﹤0.01% 4109
2023
Q4 		$172K Buy
+656
New +$119K ﹤0.01% 4479

Other funds holding LYRA

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Barclays's LYRA Position: Q3 2025 in Review

Barclays sold out of LYRA THERAPEUTICS INC (LYRA) in Q3 2025, closing a stake of 48 shares — an estimated $430 sold.

Barclays first reported a position in LYRA in Q4 2023 and held it in 7 quarters. The position peaked at $204K in Q1 2024. 26 funds tracked by Wall St. Rank hold LYRA as of Q3 2025.

  • Barclays reported no remaining LYRA THERAPEUTICS INC position as of Q3 2025 after selling out during the quarter.
  • Barclays sold 48 LYRA THERAPEUTICS INC shares in Q3 2025, an estimated $430.
  • Barclays first reported a position in LYRA THERAPEUTICS INC in Q4 2023 and held it in 7 quarters.
  • Barclays's LYRA THERAPEUTICS INC position peaked at $204K in Q1 2024.
  • 26 funds tracked by Wall St. Rank held LYRA THERAPEUTICS INC as of Q3 2025.

Based on Barclays's 13F filing for Q3 2025, filed 12 Nov 2025.